GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...

These four S&P 500 stocks pay 6% and higher dividends, have Buy ratings at top Wall Street firms, and are offering excellent entry points.

The FDA approved subcutaneous nivolumab for solid tumors, tiselizumab for advanced gastric and GEJ cancers, and key 2024 breast cancer breakthroughs are reviewed. Experts provide perspective on ...

Pfizer said Thursday its drug Ibrance showed efficacy in a group of breast cancer patients who do not currently have access to the medicine, potentially expanding its use. Ibrance, which generates ...

The trial demonstrated that the addition of IBRANCE (palbociclib) to current standard-of-care first-line maintenance therapy (following induction chemotherapy) resulted in statistically ...

Pfizer's PATINA trial shows IBRANCE boosts progression-free survival in HR+/HER2+ metastatic breast cancer by over 15 months. Median PFS reached 44.3 months with IBRANCE plus standard anti-HER2 ...

While under competitive pressure from Novartis and Eli Lilly, Pfizer can tally up a unique trial win for its Ibrance in a niche breast cancer population. Although CDK4/6 inhibitors such as Ibrance ...

The U.S. continues to charge significantly higher prices for prescription drugs compared with similarly wealthy countries.

(RTTNews) - Pfizer Inc. (PFE), on Thursday, announced positive results from the Phase 3 PATINA trial, evaluating the addition of IBRANCE for treating metastatic breast cancer. The trial ...

Healthcare giant Pfizer’s IBRANCE (palbociclib) as a combination therapy has improved progression-free survival from a Phase III trial in patients with metastatic breast cancer. Unveiled ...

The increases are to list prices, which do not include rebates to pharmacy benefit managers and other discounts.